Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancer

2022-08-23T12:18:30+00:00
  • Nanostics’ biomarker and machine learning-powered test, ClarityDX Prostate®, received a CE-IVD Mark.
  • A CE-IVD Mark is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area, Iceland, Norway, and Liechtenstein and allows Nanostics to market and sell ClarityDX Prostate® in these countries.
  • The ClarityDX Prostate® test provides patients and physicians with an accurate prediction of clinically significant prostate cancer to support decision-making and improve health outcomes for men suspected of having prostate cancer.
Press Release
Press Release: Nanostics Receives CE Mark for its ClarityDX Prostate® Test to Detect Clinically Significant Prostate Cancer2022-08-23T12:18:30+00:00

Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer

2022-07-20T13:09:06+00:00
  • Clinical study launched in June 2022 with patient recruitment in Alberta with plans to expand to further sites across North America.
  • The aim of the study is to validate a novel and minimally invasive liquid biopsy test for bladder cancer diagnosis using Nanostics’ ClarityDX® diagnostic platform.
  • The study is supported in part by the Alberta Innovates AICE-Concepts Program with a $600,000 award to Dr. John Lewis, Bird Dogs Chair in Translational Cancer Research at the University of Alberta.
Press Release
Press Release: Nanostics Announces the Launch of its Bladder Cancer Clinical Study Identifying Disease Predictors for Early Detection of Bladder Cancer2022-07-20T13:09:06+00:00

Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer

2022-06-30T12:14:03+00:00

Real-world data shows that at a 94% sensitivity level for prostate cancer ClarityDX Prostate® is 147% more specific than the PSA test for predicting clinically significant prostate cancer. Using ClarityDX Prostate® as a reflex test vs. PSA test alone could have resulted in 37% fewer unnecessary biopsies.

Press Release
Press Release: Nanostics Announces Study Data Supporting ClarityDX Prostate as a Reflex Test to Predict Clinically Significant Prostate Cancer2022-06-30T12:14:03+00:00

Nanostics Welcomes New Board Member Mike Schoenberger

2022-02-05T03:16:10+00:00

Nanostics is EXCITED to announce Mike Schoenberger as its newest Board Member! We also send a huge THANK YOU to outgoing board member Dale Klein for his dedicated service.

Full Article
Nanostics Welcomes New Board Member Mike Schoenberger2022-02-05T03:16:10+00:00

Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site

2022-01-04T19:06:51+00:00

PR: Nanostics announced the re-opening of their clinical validation study testing ClarityDX Prostate in a real-world setting. The study is also greatly benefiting from further expansion into the US with the addition of a new patient recruitment site at an award-winning United States clinical research institution. ClarityDX Prostate is a novel liquid biopsy test for the early diagnosis of clinically significant prostate cancer. Nanostics is excited to work with this Partner to reach the recruitment numbers and diversity goals of the clinical study.

Full Article
Nanostics Re-Opens ClarityDX Prostate Clinical Study with New US Recruitment Site2022-01-04T19:06:51+00:00

Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients

2022-01-04T19:08:02+00:00

PR today: Nanostics to use ClarityDX platform to develop & validate a blood test to predict COVID-19 severity in SARS-CoV-2 patients; with Canadian BioSample Repository in Alberta and Century Clinical Research Institute in Florida.

Full Article
Nanostics is Developing and Validating a Simple Blood Test to Predict Severity of COVID-19 Disease in SARS-CoV-2 Positive Patients2022-01-04T19:08:02+00:00

Alberta Impact with Bryce Lambert, Episode 3, ‘Future of Health’ DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab program

2022-01-04T19:08:38+00:00

Your technology’s proven in an academic lab⎯now you want it adopted into the healthcare system. The DynaLIFE Accelerator helps startups develop and validate tests in a real-world setting.

Full Article
Alberta Impact with Bryce Lambert, Episode 3, ‘Future of Health’ DynaLIFE Accelerator Lab; benefits of this amazing Medical Lab program2022-01-04T19:08:38+00:00

Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT03957252

2022-01-04T19:09:09+00:00

Clinical study to validate ClarityDX Prostate as a reflex test to high PSA levels to refine prediction of clinically significant prostate cancer has begun in a prospective cohort of 2800 men.

Full Article
Validation of ClarityDX Prostate as a Reflex Test to Refine Prediction of Clinically Significant Prostate Cancer: ClinicalTrials.gov ID: NCT039572522022-01-04T19:09:09+00:00

CBC News-Biotech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives

2022-01-04T19:09:39+00:00

Alberta-based Nanostics is hoping to recruit 200 Yukoners to the clinical validation study testing ClarityDX Prostate in a real-world setting.

Full Article
CBC News-Biotech firm recruiting Yukon men for trial, Prostate cancer group says it could save lives2022-01-04T19:09:39+00:00

CKRW 96.1 FM Radio-Cancer Study Comes to the Yukon

2022-01-04T19:10:13+00:00

The Yukon Ride for Dad, which raises money for prostate cancer awareness and research, is making a substantial investment in Nanostic’s research into diagnostic testing for prostate cancer.

Full Article
CKRW 96.1 FM Radio-Cancer Study Comes to the Yukon2022-01-04T19:10:13+00:00
Go to Top